### PATENT COOPERATION TREATY

## **PCT**

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Form PCT/PEA/416		
SF-1099				
International application No. PCT/JP2004/015457	International filing date (day/month/year) 13.10.2004	Priority date (day/month/year) 14.10.2003		
International Patent Classification (IPC) or national classification and IPC A61K7/48, C07D307/62				
Applicant SHOWA DENKO K.K.				
	iminary examination report, established smitted to the applicant according to Ar	by this International Preliminary Examining ticle 36.		
. This REPORT consists of a total of 7 sheets, including this cover sheet.				
This report is also accompanied by ANNEXES, comprising:				
a.   sent to the applicant and to the International Bureau) a total of sheets, as follows:				
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
		y considers contain an amendment that goes as indicated in item 4 of Box No. I and the		
sequence listing and/or tab		number of electronic carrier(s)) , containing a e form only, as indicated in the Supplemental rative Instructions).		
4. This report contains indications rel	lating to the following items:			
☑ Box No. I Basis of the opin	ion			
☐ Box No. II Priority				
_	ent of opinion with regard to novelty, inve	entive step and industrial applicability		
☐ Box No. IV Lack of unity of i				
applicability; cita	ment under Article 35(2) with regard to r tions and explanations supporting such			
☑ Box No. VI Certain documer				
☐ Box No. VII Certain defects i				
⊠ Box No. VIII Certain observat	tions on the international application			
Date of submission of the demand	Date of completion	on of this report		
07.03.2005	02.11.2005			
Name and mailing address of the international	al Authorized Office			
preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 52365	Miller, B	The state of the s		
Fax: +49 89 2399 - 4465	Telephone No. +	49 89 2399-		

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

IAP20 Recid Collaboration Appetable.
PCT/JP2004/015457

	Box No. I Basis of the report	t	
1.	With regard to the <b>language</b> , this report is based on the international application in the language in which it villed, unless otherwise indicated under this item.		
	which is the language of a  international search (un  publication of the internation	nslations from the original language into the following language, translation furnished for the purposes of: der Rules 12.3 and 23.1(b)) ational application (under Rule 12.4) v examination (under Rules 55.2 and/or 55.3)	
2.	. With regard to the <b>elements*</b> of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):		
Description, Pages			
	1-58	as originally filed	
Claims, Numbers			
	1-18	as originally filed	
	☐ a sequence listing and/or a	ny related table(s) - see Supplemental Box Relating to Sequence Listing	
3.	The amendments have resulted in the cancellation of:  ☐ the description, pages ☐ the claims, Nos. ☐ the drawings, sheets/figs ☐ the sequence listing (specify): ☐ any table(s) related to sequence listing (specify):		
4.	☐ This report has been estable had not been made, since they Supplemental Box (Rule 70.2(c☐ the description, pages☐ the claims, Nos.☐ the drawings, sheets/figs☐ the sequence listing (sp☐ any table(s) related to s	s ecify):	
	* If item 4 applies, s	ome or all of these sheets may be marked "superseded."	

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

5,8-10

No: Claims

1-4,6-7,11-18

Inventive step (IS)

Yes: Claims

No: Claims

1-18

Industrial applicability (IA)

Yes: Claims

1-18

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

#### Box No. VI Certain documents cited

1. Certain published documents (Rule 70.10)

and /or

2. Non-written disclosures (Rule 70.9)

see separate sheet

#### Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

## 10/575624

## IAP20 RecidirCT/PTO 13 APR 2006

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET) International application No.

PCT/JP2004/015457

#### Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- Novelty (Article 33(2) PCT)
   The present application does not meet the criterion set forth in Article 33(2) PCT because the subject-matter of claims 1-4,6,7,11-18 is not new in respect of the prior art as defined in the regulations (Rule 64(1)-(3) PCT).
- 1.1. The following documents disclose already compositions falling within the scope of present claim 1-4,6,7,11-13.
- a) EP-A- 1 077 066 (D1) discloses cosmetic compositions (example 8: cream) comprising 6 wt.-% propylene glycol and 7 wt.-% sodium 6-palmitoyloxy-L-ascorbic acid-2-phosphate. A similar composition (ointment) is shown in example 10 comprising as polyhydric alcohols 12 wt.-% of propylene glycol and 1 wt.-% of a glycerin derivative and additionally two ascorbic acid derivatives (6-palmitoyloxy or 6-stearoyloxy-L-ascorbic acid-2-phosphate salt).
- b) XP-002073274 (D2) reports skin cosmetics comprising 4 wt.-% 6-dodecanoylascorbic acid-2-phosphate Mg salt and 8 wt.-% of glycerin.
- c) JP-A-2003-267856 (D3) discloses cosmetic creams (paragraph [0073]-[0076]) comprising butylene glycol, glycerol and sodium 6-palmitoyloxy-L-ascorbic acid-2-phosphate.
- d) **JP-A-2003-176217** (D4) discloses cosmetic creams (paragraph [0030]-[0035]) comprising propylene glycol and sodium 6-palmitoyloxy-L-ascorbic acid-2-phosphate.
- 1.2. Claim 14 is directed to a cosmetic composition comprising the composition according to claim 1. Thus, the same argumentation with respect to novelty applies to claim 14 as for claim 1.
- 1.3. Claim 15 is directed to a method. Said method is defined by the presence of two components. Since the compositions exemplified in documents D1-D4 are stable compositions, the method according to present claim 15 is implicitly known from said documents.

1.4. Claim 17 is directed to a stabilizer which is defined by the component which should be stabilized.

However, the indication of an intended use is not a distinguishing feature (Guidelines, Chapter 12.05) which has to be considered when evaluating novelty.

Thus, claim 17 is directed simply to polyhydric alcohols. Such polyhydric alcohols (e.g. glycerin) are known in the art for more than 100 years. Specific representatives are e.g. mentioned in document D1(examples): dipropylene glycol, sorbitol.

Thus, the subject-matter of claims 17 and 18 also lacks novelty.

- 2. **Inventive Step** (Article 33(3) PCT)
- 2.1. The present application is directed to cosmetic compositions for skin external use comprising an ascorbic acid derivative.

The documents D1-D4 cited above relate to the same general field as the present application and all describe stable cosmetic compositions comprising the same type of ascorbic acid derivative as defined by claim 1 of the present application.

Thus any of these documents can be regarded as the closest prior art for the subjectmatter of present claims 5, 8-10.

The subject-matter of said claims differs from the teaching of documents D1-D4 in that an alternative fatty acid residual (R group) is used (present claim 5) or in that alternative polyhydric alcohols are present (present claims 8-10).

Thus, the objective technical problem has to be regarded as to provide alternative compositions.

Arbitrarily changing the length of the R residue or replacing arbitrarily the cosolvent (e.g. glycerin, propylene glycol) used according to D1-D4 by an equivalent alcohol (e.g. dipropylene glycol) comes within the routine practice of the skilled person, in particular since it is known e.g. from document D1 that salts of ascorbic acid derivatives are soluble in dipropylene glycol (D1: formulation example 3).

Moreover, the present application is silent with respect to advantages achieved by using specific alcohols or specific ascorbic acid derivatives. In fact, most of the examples of the present application make use of exactly the same components as used according to D1-D4.

The solution proposed in claims 5,8-10 of the present application thus cannot be considered as involving an inventive step (Article 33(3) PCT).

2.2. Furthermore it is observed, that several examples indicated as examples according to the invention (examples 1,2,5,6,16) do not achieve better results than the corresponding comparative examples. Thus it seems that the underlying problem to be solved (providing a stable composition) is not achieved over the whole scope of protection. Thus, the subject-matter of claim 1 lacks an inventive step (Article 33(3) PCT).

#### Re Item VI

#### Certain documents cited

#### Certain published documents

Application No Patent No Publication date (day/month/year)

Filing date (day/month/year)

Priority date (valid claim) (day/month/year)

WO-A-03/086384

23.10.2003

11.04.2003

12.04.2002

**WO-A-03/086384** (D5) discloses skin care compositions (examples) comprising L-ascorbic acid-2-phosphate-6-alkylate salt (e.g. hexyldodecanoate) and poylhydric alcohol (glycerin, glycol).

#### Re Item VIII

#### Certain observations on the international application

The following observations on the clarity of the claims and description or on the question whether the claims are fully supported by the description are made:

- 1. The term "higher fatty acid residual group" in present claim 1 has no well defined and precise meaning, contrary to Article 6 PCT.
- When filing amended claims the applicant should at the same time bring the description into conformity with the amended claims. Care should be taken during revision, especially of the introductory portion and any statements of problem or advantage, not to add subject-matter which extends beyond the content of the application as originally filed (Article 34(2)(b) PCT).

The applicant should clearly identify the amendments carried out, irrespective of

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/JP2004/015457

whether they concern amendments by addition, replacement or deletion, and to indicate accurately the passages of the application as filed on which these amendments are based (Rule 66.8 (a) PCT).

The amendments are preferred to be carried out in handwritten form on a copy of the relevant parts of the application as filed (Rule 66.8 (b) PCT) accompanied by a clean copy of the corresponding pages (Guidelines PCT/GL/ISPE/1, Chapter 20.6-20.8).